With increasing survival times among cancer patients, the management of metastatic bone tumors and their recurrence is an increasingly common challenge. Recent studies and evidence-based reviews support single-dose palliative radiotherapy, which reduces the physical burdens of multifraction regimens followed by, upon recurrence, with re-irradiation or tumor ablation using emerging treatment modalities such as image-guided ultrasound. 

Bone is the third most frequent site for metastatic tumors, after the lungs and the liver.1 Bone metastases represent the single most frequent cause of pain among cancer patients; often excruciating and debilitating, it commonly leads to a profound decrease in quality of life during cancer patients’ final months and weeks of life.2,3 Prognosis among patients with bone metastases can vary markedly. Median lung cancer survival times are shorter than 6 months, whereas median prostate cancer survival times are as long as 40 months.4  

Bone metastases can be osteolytic (bone-destroying), osteoblastic, or mixed.2 When spinal compression or pathogenic fractures result, metasatases are said to be complicated. Common complications include pathogenic bone fractures, hypercalcemia, and spinal cord compression.3 Treatment includes bisphosphonates for osteoblastic or mixed bone tumors, and corticosteroids and surgery for pathogenic fractures.2,4 Denosumab (Prolia, Xgeva) is approved for prevention of fractures in patients with bone metastases.4 Bone-seeking radiopharmaceuticals such as Sr-89, Sm-153, and Re-186 also show promise as a palliative modality for painful bone metastases.5,6

But external-beam radiotherapy (EBRT) remains the gold standard for metastatic bone tumor palliation, particularly for uncomplicated tumors, among patients who are experiencing bone pain.3 However, justification of palliative EBRT for asymptomatic bone metastases is controversial.7 EBRT can improve function and reduce the need for analgesics (which are not always effective for bone tumor pain). Not surprisingly, patients whose pain is relieved by radiotherapy enjoy better quality of life.8


Numerous studies have shown single-fraction radiotherapy is as effective as multifraction treatments, but doses and fractionation schedules continue to vary among treatment facilities.1,3,9 In 2009, researchers in Canada and the United States reported that most radiation oncologists prescribed multiple radiation dose fractions for palliation of metastatic bone pain.9 Whether multiple-dose treatments are justified in most cases of uncomplicated bone tumor pain is questionable, given the efficacy of single-dose treatments and the additional costs and physical burdens of multiple-fraction regimens, particularly for elderly patients.10

In 2011, the American Society for Radiation Oncology (ASTRO) released evidence-based treatment guidelines for palliative radiotherapy of metastatic bone tumors.3 The guidelines, based on a systematic review of 25 randomized clinical trials, 20 single-armed prospective studies, and four meta-analyses, conclude that safe and effective EBRT can be delivered in a single 8-Gy dose fraction.3

A subsequent 2013 systematic review of 26 randomized controlled clinical trials—the first published systematic review of data on the relative efficacy of different EBRT doses—concluded that “8 Gy should be the standard dose against which future treatments are compared due to its reproducible pain response rate and its established safe profile.”11 But the authors were quick to note that the research literature does not include enough dose variation for a great enough number of patients to quantify a dose/response relationship between single-fraction radiation dose and efficacy of bone tumor pain relief.11 Although the available research literature illustrates that a single dose of 8 Gy is clearly superior to 4 Gy, the optimal dose for bone pain relief is yet to be established.11 Indeed, a dose/response relationship might not exist, the authors note; there may simply be a threshold dose between 4 Gy and 8 Gy at which pain relief is achieved but higher doses offer no additional improvement.11

International guidelines for palliative radiotherapy clinical trials have also been promulgated, that might help answer open questions about dosing. If widely adopted, the guidelines will promote consistent methodologies and endpoints, and facilitate future evidence-based reviews and interpretations of the clinical trial literature.12